Join to access to all OVN content. Join for Free
Life After Medical Affairs: From MSL to M & A
St. Onge MSL to Business Development Paratek career transition overcoming glass ceiling in medical affairs LinkedIn for career advancement

Life After Medical Affairs: From MSL to M & A


Share This Article


Summary

In this episode, Steve St. Onge shares his unique journey from traditional MSL roles to business development at Paratek. He discusses his background, transition to industry, and involvement in nontraditional MSL work. Steve delves into the challenges faced during his shift to business development and highlights essential skills for success in this area. The conversation also touches on overcoming the glass ceiling in medical affairs and leveraging medical affairs expertise in business roles. Steve offers valuable advice for MSLs considering a move into M&A or business development, emphasizing the importance of company research and utilizing LinkedIn for career advancement.

This episode features Steve St. Onge, Sr Director Business Development at Paratek discusses his career path from Medical Affairs to Business Development (M and A) and how he got there
We discuss….

👉 How he transitioned from Medical Affairs to M and A
👉 What his role in Business Development and M and A entails
👉 The difference between Corporate Development and Business Development
👉 Why LinkedIn can be an MSLs worst enemy
👉 The “glass ceiling” in Medical Affairs
👉 Why you need to learn the DNA of a company

Click for Source
St. Onge, MSL to Business Development, Paratek career transition, overcoming glass ceiling in medical affairs, LinkedIn for career advancement

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN